Advertisement
Advertisement
CORT
Corcept Therapeutics Inc.
74.53
USDSponsored
+1.18
+1.61%
Nov 11, 16:00 UTC -5
Closed
After-Market
74.76
+0.23
+0.31%
Corcept Therapeutics Inc. (CORT) Earnings
CORT Earnings Reports
Positive Surprise Ratio
CORT beat 28 of 44 last estimates.
64%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$391.81M
/$1.10
Implied change from Q3 26 (Revenue/ EPS)
+15.08%
/+8.91%
Implied change from Q4 25 (Revenue/ EPS)
+93.84%
/+450.00%
Corcept Therapeutics Inc. earnings per share and revenue
On Nov 03, 2026, CORT reported earnings of 1.01 USD per share (EPS) for Q3 26, beating the estimate of 0.80 USD, resulting in a 24.71% surprise. Revenue reached 340.47 million, compared to an expected 343.10 million, with a -0.77% difference. The market reacted with a -3.31% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 1.10 USD, with revenue projected to reach 391.81 million USD, implying an increase of 8.91% EPS, and increase of 15.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.56
Actual
-$0.46
Surprise
+19.06%
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
PolyPid Ltd. Ordinary Shares
Report Date
Nov 11, 2026 For Q3 26
Estimate
$0.05
Actual
-$0.24
Surprise
-508.16%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
FAQ
What were Corcept Therapeutics Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Corcept Therapeutics Inc. reported EPS of $1.01, beating estimates by 24.71%, and revenue of $340.47M, -0.77% below expectations.
How did the market react to Corcept Therapeutics Inc.'s Q3 2026 earnings?
The stock price moved down -3.31%, changed from $81.93 before the earnings release to $79.22 the day after.
When is Corcept Therapeutics Inc. expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Corcept Therapeutics Inc.'s next earnings report?
Based on --
analysts, Corcept Therapeutics Inc. is expected to report EPS of $1.10 and revenue of $391.81M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.